Maya Savira1,2, Donel Suhaimi3, Andani Eka Putra4, Yusrawati Yusrawati5, Nur Indrawati Lipoeto6. 1. Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia. 2. Microbiology Department, Faculty of Medicine, Universitas Riau, Pekanbaru, Riau, Indonesia. 3. Obstetry & Gynecology Department, Faculty of Medicine, Universitas Riau, Arifin Achmad General Hospital, Pekanbaru, Riau, Indonesia. 4. Microbiology Department, Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia. 5. Obstetry & Gynecology Department, Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia. 6. Clinical Nutrition Department, Faculty of Medicine, Andalas University, Padang, West Sumatera, Indonesia.
Abstract
Background: Cervical cancer is the fourth most deadly cancer in the world, and it is caused by infection of high-risk subtypes of Human PapillomaVirus (HPV) in most cases. The aims of this study were to determine the prevalence oncogenic HPV in cervical cancer patients in Riau Province Indonesia and to determine the clinical manifestation of HPV in cervical cancer patients in Riau Province Indonesia. Methods: This research was a descriptive study conducted at Arifin Achmad General Hospital Riau from February to August 2018 which aimed to analyze HPV genotype prevalence oncogenic of cervical cancer patients. Results: This study showed out 86 of 110 women (78.1%) were found HPV positive, and the most common genotype of HPV was HPV 16 (38.2%). The average age of cervical cancer patient was 50 years old, and the average number of parities was 4 times. The majority of participants were married at the age before 20 years (77.3%) and had low educational background (64.5%). Vaginal bleeding happened in more than half of the participant as major clinical manifestation (72.7%), followed by fluor albus (72.7%), pelvic pain (60.2%) and fatigue (65.9%). Conclusion: The most common HPV genotype in Riau Province was HPV type 16 and the most common clinical symptoms of cervical cancer patient were vaginal bleeding, fluor albus, pelvic pain and fatigue.
Background: Cervical cancer is the fourth most deadly cancer in the world, and it is caused by infection of high-risk subtypes of Human PapillomaVirus (HPV) in most cases. The aims of this study were to determine the prevalence oncogenic HPV in cervical cancer patients in Riau Province Indonesia and to determine the clinical manifestation of HPV in cervical cancer patients in Riau Province Indonesia. Methods: This research was a descriptive study conducted at Arifin Achmad General Hospital Riau from February to August 2018 which aimed to analyze HPV genotype prevalence oncogenic of cervical cancer patients. Results: This study showed out 86 of 110 women (78.1%) were found HPV positive, and the most common genotype of HPV was HPV 16 (38.2%). The average age of cervical cancer patient was 50 years old, and the average number of parities was 4 times. The majority of participants were married at the age before 20 years (77.3%) and had low educational background (64.5%). Vaginal bleeding happened in more than half of the participant as major clinical manifestation (72.7%), followed by fluor albus (72.7%), pelvic pain (60.2%) and fatigue (65.9%). Conclusion: The most common HPV genotype in Riau Province was HPV type 16 and the most common clinical symptoms of cervical cancer patient were vaginal bleeding, fluor albus, pelvic pain and fatigue.
Entities:
Keywords:
Cervical cancer; Clinical manifestations Human Papilomavirus; Human Papilomavirus genotype prevalence
Authors: Jiafeng Pan; Kimberley Kavanagh; Kate Cuschieri; Kevin G Pollock; Duncan C Gilbert; David Millan; Sarah Bell; Sheila V Graham; Alistair R W Williams; Margaret E Cruickshank; Tim Palmer; Katie Wakeham Journal: Int J Cancer Date: 2019-03-04 Impact factor: 7.396
Authors: Gordana Kovacevic; Vesna Milosevic; Petar Knezevic; Aleksandra Knezevic; Ivana Knezevic; Jelena Radovanov; Natasa Nikolic; Aleksandra Patic; Vladimir Petrovic; Ivana Hrnjakovic Cvjetkovic; Ljiljana Stanisic Journal: Biologicals Date: 2019-02-20 Impact factor: 1.856
Authors: Aixa M Pérez-Caraballo; Erick Suarez; Elizabeth R Unger; Joel M Palefsky; Gitika Panicker; Ana Patricia Ortiz Journal: P R Health Sci J Date: 2018-03 Impact factor: 0.705